Skip to main content
Premium Trial:

Request an Annual Quote

Rat Genome, Tripos, Accelrys, Clinomics Biosciences, Spotfire, Inpharmatica, Geospiza


Bioinformatics Groups Tackle Rat Genome

The publication of the genome sequence of the brown Norway laboratory rat in Nature last week was accompanied by a barrage of bioinformatics data analyses in a special issue of Genome Research ( The April issue of the journal contains 30 papers describing in-depth analyses of the draft sequence, as well as several methods papers, including a description of the Atlas algorithm used to assemble the genome.

The genome was assembled at Baylor College of Medicine, and subsequent analysis was performed by over 20 groups in six countries using gene and protein predictions from the Ensembl project.

Tripos Releases Q4 ‘03 Earnings, Restates Prior Results

Tripos last week reported its financial results for the fourth quarter and full year ended Dec. 31, 2003, along with its restated financial results for prior years.

For the full year of 2003, Tripos posted revenues of $54.1 million, a 10 percent increase from the previous year’s revenues of $49.1 million. Revenues for the fourth quarter were down, however, to $12.6 million compared to $14.7 million in the fourth quarter of 2002.

Net income for 2003 was $2.1 million, and the company posted a $500,000 net loss for the quarter.

Tripos spent $2.7 million on R&D in the fourth quarter of 2003, up slightly from $ 2.6 million a year ago.

The company had $2.9 million in cash and cash equivalents as of Dec. 31, 2003.

Accelrys to Resell IBM Tools Via Avnet

Accelrys last week said that it would work with IT distributor Avnet Hall-Mark to resell IBM hardware solutions through Avnet’s Enablement Services Partnership program.

The agreement builds upon an existing partnership between IBM and Accelrys, and will allow Accelrys to design, market, and finance IBM solutions on demand.

AZ Licenses Clinomics’ Cell-Signaling Database

Cytomyx Holdings said last week that that its subsidiary Clinomics Biosciences has licensed its Oncology Cell Signaling Database to AstraZeneca.

AstraZeneca has purchased multiple user licenses to the database, which contains protein expression patterns for 100 cell-signaling proteins from more than 30,000 human oncology samples.

Spotfire Sells DecisionSite to Wyeth

Spotfire said last week that Wyeth’s Discovery Research Group has licensed its DecisionSite software.

Wyeth will deploy DecisionSite for Functional Genomics, DecisionSite for Lead Discovery, and DecisionSite Statistics at four discovery sites: Cambridge, Mass.; Collegeville, Pa.; Pearl River, NY; and Princeton, NJ.

Taisho Takes License to Biopendium

Inpharmatica said it has licensed its Biopendium Online genome annotation database to Taisho Pharmaceuticals of Japan.

Taisho is the third Japanese subscriber to Biopendium, and the first to choose the online version, Inpharmatica said.

Geospiza Sells Invoice Software to Hopkins Lab

Geospiza has sold a license for its newly released Finch Customer Invoice Manager to Johns Hopkins University’s Genetic Resources Core Facility.

The application works in conjunction with Geospiza’s Finch Sequencing Center to assist core labs with job invoices, billing, and other financial transactions related to DNA sequencing projects.

Filed under

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.